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Abstract: 
Structure-based virtual screening (SBVS) protocols were developed to find cyclooxygenase-2 (COX-2) inhibitors using the Protein-Ligand ANT System 
(PLANTS) docking software. The directory of useful decoys (DUD) dataset for COX-2 was used to retrospectively validate the protocols; the DUD consists of 426 
known inhibitors in 13289 decoys. Based on criteria used in the article describing DUD datasets, the default protocol showed poor results. However, having 
ARG513 as a hydrogen bond anchor increased the quality of the SBVS protocol. The modified protocol showed results that could be well considered, with a 
maximum enrichment factor (EFmax) value of 32.2. 
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Background: 
Molecular docking, used in structure-based virtual screening (SBVS) 
campaigns, is considered a powerful tool in drug discovery [1-3]. Some drugs 
on the market, e.g., Dorzolamide
® (Merck & Co) [4], Saquinavir
® (Hoffmann-
La Roche) [5], Indinavir
® (Merck & Co.) [5], Ritonavir
® (Abbott Laboratories) 
[5] and Nelfinavir
® (Agouron Pharmaceuticals) [5], were discovered or 
designed using this approach [2]. Some limitations of the molecular docking 
method have been identified and have led to fruitful discussions [6, 7]. The 
primary challenge was to improve the quality of the scoring functions, which 
determines the ranking of the compounds in SBVS [6, 7]. Most of the available 
scoring functions were developed as all-purpose models, which can presumably 
be applied in all protein-ligand complexes. However, despite the considerable 
progress in the development of scoring functions, they are still far from being 
universally accurate [6, 7]. Therefore, using prior knowledge and targeted 
scoring functions in the construction of the SBVS protocols can be a useful 
solution [6]. Cyclooxygenase-2 (COX-2) is an enzyme that plays an important 
role in inflammatory processes [8]. The dataset, which was compiled from the 
ZINC database (http://zinc.docking.org/) to retrospectively validate and 
compare SBVS protocols to find COX-2 inhibitors, is publicly available in the 
directory of useful decoys (http://dud.docking.org/r2/cox2.tar.gz). The enzyme 
has been considered a challenging target for SBVS campaigns [9, 10]. For the 
first SBVS campaign, a dataset from the directory of useful decoys (DUD) was 
used to find COX-2 inhibitors by employing the DOCK 3.5.54 docking 
software. The results showed a maximum enrichment factor (EFmax) value and 
an enrichment factor value at 20% of the database (EF20) of 29.1 and 3.3, 
respectively [9], which were considered as good results [9]. We had previously 
described the applicability of the Protein-Ligand ANT System (PLANTS) 
docking software to reproduce the crystal structure interaction of 1-
phenylsulfonamide-3-trifluoromethyl-5-parabromophenyl-pyrazole (1) with 
COX-2 (pdb code: 6COX; http://dx.doi.org/10.2210/ pdb6cox/pdb) [11, 12]. In 
this article, we present the retrospective validation of a developed protocol to 
perform as a screening tool for the discovery of COX-2 inhibitors using SBVS 
campaigns. Additionally, the construction of a modified protocol is displayed 
by inserting an additional constraint to the hydrogen bond formed by ligands to 
ARG513 of the COX-2 since previously published studies indicate that this 
particular interaction is important for COX-2 inhibitors [11, 13]. Although the 
default protocol could reproduce the structural interactions from the crystal 
structure [12], the results showed that the protocol showed poor results as an 
SBVS campaign to discover COX-2 inhibitors. Conversely, the modified 
protocol resulted in excellent EFmax and EF20 values [9]. 
 
Methodology: 
The COX-2 ligands and decoys (426 known inhibitors in 13289 decoys) were 
obtained from the DUD website (http://dud.docking.org/r2/) [9]. The target 
enzyme, virtual COX-2 (protein.mol2), and the PLANTS configuration file 
(plantsconfig) were obtained from a previous study [12]. The PLANTS 
docking software v1.1 was used as the SBVS docking tool (http://www.tcd.uni-
konstanz.de/research/plants.php). The receiver operator characteristic (ROC) 
curves were calculated using R statistical computing software version 2.11.1 
(http://www.r-project.org/). All computational simulations were performed on 
an HP-xw6600 workstation with Intel Xeon E5420/2.5 GHz Quadcores as the 
processors, 8 GB of RAM and a Linux version 2.6.26-2-amd64 (Debian 2.6.26-
26lenny1) as the operating system. The compounds were virtually screened 
using the PLANTS docking software by employing a previously developed 
virtual COX-2 as the target [12]. Two independent simulations were 
performed: (i) original protocol (using previously described config file BIOINFORMATION  open access 
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(plantsconfig))  [12] and (ii) modified protocol (original protocol with a 
constraint to atom number 7808 (Hydrogen bond to ARG513; 
mod_plantsconfig). The compounds were then ranked based on their scores, 
and ROC curves were calculated and generated. The quality of the screening 
procedures was judged using criteria introduced by Huang et al. [9]. The paired 
t-test of the true positive rate values was performed to analyze the importance 
of hydrogen bonding at ARG513, which would aid in the discovery of COX-2 
inhibitors. The configuration files used in these screenings are available in 
Supplementary material. 
 
 
Figure 1: (A) ROC curves (percent of known ligands found vs. percent of 
ranked database). The results from the ideal, default, and modified protocols 
and random picking are presented in solid black, green, red and dashed black 
curves, respectively. (B) Curve of φ values vs. percent of ranked database. A 
red point indicates the coordinate of the suggested reference compound, 
ZINC03814717. (C) Compound ZINC03814717 (the 2D structure is shown as 
an inset) in the binding pocket of COX-2 together with the crystal structure of 
compound 1 (the 2D structure is shown as an inset) [11]. Only residues forming 
hydrogen bonds are shown here. The residues are presented as lines, and the 
ligands are presented as sticks. Carbon atoms are presented in green for COX-
2, magenta for compound 1 and cyan for compound ZINC03814717. Polar 
hydrogen atoms are presented in white, fluorine atoms are presented in light 
blue, nitrogen atoms are presented in blue, oxygen atoms are presented in red, 
and sulfur atoms are presented in yellow. Dashed black lines indicate the 
hydrogen bonds. The 3D figure was created using PyMOL 1.2 
(http://www.pymol.org/). 
 
Results and Discussion: 
The ROC curves are presented in Figure 1A. The figure shows that the 
modified protocol provided better results compared to the results from the 
default protocol. The EFmax and EF20 values of the SBVS using the default 
protocol were 1.8 and 1.5, respectively. However, the modified protocol 
showed EFmax and EF20 of 32.2 and 3.7, respectively. Referring to standards 
determined by Huang et al. [9], the quality of the SBVS default protocol has 
been considered poor, while the modified protocol can be considered very 
good. Moreover, the paired t-test of true positive values provided a significance 
value of less than 0.05. This showed that the modified protocol at a 95% level 
of confidence differed significantly compared to the default method for the 
screening COX-2 inhibitors. This data supports previous hypotheses that the 
hydrogen bond formation between ligands and ARG513 is important for COX-
2 inhibition [11, 13]. This also confirmed that inputting prior knowledge into 
the protocol could increase the quality of the SBVS [6]. Furthermore, this result 
provided a valid protocol that could be used to perform virtual screening to 
design and discover COX-2 inhibitors. The computational time needed to 
perform each retrospective validation is about 80 hours. It is not efficient to 
perform similar validation to avoid calculation instability caused by differences 
in the computer systems used in the screening. Therefore, we suggest selecting 
a single compound as the reference compound. The compound can be selected 
by calculating the Matthews correlation coefficient (φ) values (Figure 1B). The 
reference compound was the compound with the highest φ value, which 
indicated the best discrimination ability compared to other known inhibitors. 
The modified protocol showed that the selected reference compound was 
ZINC03814717 (shown as an inset in Figure 1C), with an enrichment factor 
value of 3.7 (EF21.01). The accuracy and sensitivity of the SBVS for EF21.01 were 
80.7% and 78.4%, respectively. Compound ZINC03814717 has been reported 
as a COX-2 inhibitor with an IC50 value of 290 nM or pIC50 of 6.54 [14]. 
Figure 1C shows the docking pose of ZINC03814717, using the modified 
protocol, in the COX-2 binding pocket together with the crystal structure of 
compound 1. Similar to the pose of compound 1 (shown as an inset in Figure 
1C), the sulfonamide moiety formed a hydrogen bond to ARG513. The 
sulfonamide moiety showed an additional hydrogen bond at the backbone of 
SER353. Remarkably, the nitro group of ZINC03814717 showed a hydrogen 
bond to SER530, which is known as a binding anchor of COX-2 ligands [15]. 
This interaction was not observed in the binding pose of compound 1 to COX-2 
[11, 12]. This indicated that there were other important interactions that could 
be used to increase the quality of the SBVS. Further experiments were 
suggested to optimize the SBVS by varying the constraint weight and the 
binding residues. 
 
Conclusion: 
A retrospective SBVS validation using the DUD dataset for COX-2 inhibitors 
showed that, although the docking protocol, i.e., the default setting on the 
PLANTS docking software, was able to accurately reproduce the crystal 
structure interaction between compound 1 and COX-2 [12], it needed 
additional constraints in the protocol to perform better SBVS. This study 
confirmed the importance of interactions between COX-2 inhibitors and 
ARG513. Using criteria introduced by Huang et al.  [9], the quality of the 
SBVS approach increased.  
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Supplementary material: 
 
plantsconfig: 
# scoring function and search settings 
scoring_function chemplp 
search_speed speed1 
 
 
# input 
protein_file protein.mol2 
ligand_file cox2_all_dud.mol2 
 
# output 
output_dir results 
 
# write single mol2 files (e.g., for RMSD calculation) 
write_multi_mol2 0 
 
# binding site definition 
bindingsite_center 23.6651 23.3126 47.8265 
bindingsite_radius 11.3323 
 
# cluster algorithm 
cluster_structures 10 
cluster_rmsd 2.0 
 
 
mod_plantsconfig: 
 
# scoring function and search settings 
scoring_function chemplp 
search_speed speed1 
 
 
# input 
protein_file protein.mol2 
ligand_file cox2_all_dud.mol2 
 
# output 
output_dir results_mod 
 
# write single mol2 files (e.g., for RMSD calculation) 
write_multi_mol2 0 
 
# binding site definition 
bindingsite_center 23.6651 23.3126 47.8265 
bindingsite_radius 11.3323 
 
#constraint 
chemplp_protein_hb_constraint 7808 10 
 
# cluster algorithm 
cluster_structures 10 
cluster_rmsd 2.0 
 
 